Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 36Cholangiocarcinoma 11Carcinoma, Renal Cell 10Stomach Neoplasms 5Liver Neoplasms 5Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasm Metastasis 2Liver Diseases 2Kidney Neoplasms 2Cirrhosis, Familial, with Pulmonary Hypertension 2Breast Neoplasms 2Advanced Solid Tumor 2von Hippel-Lindau Disease 1Urogenital Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Penile Neoplasms 1

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Gastric Adenocarcinoma × lenvatinib × Clear all
NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
15 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡